VACCINE
Continued from Page 18
less herpes virus with which most people are already
infected. OHSU’s CMV-based vaccine platform has
already demonstrated promising pre-clinical efficacy
against HIV and TB. The CMV-based HIV vaccine, for
example, is headed into human clinical trials that will
be managed by San Francisco-based Vir Biotechnol-
ogy, which licensed the technology from OHSU.
So the million-dollar question is, will this new ap-
proach work? We’ll test our CMV-based flu vaccine’s
effectiveness against one of the worst flu strains ever:
the 1918 pandemic flu strain, which killed 50 million
people worldwide. Within two years, we’ll know if
our CMV-based flu vaccine can fight off the 1918 flu
strain. If it can beat that, it can probably beat any flu
strain. And while we don’t know for sure if it’ll work,
I’m proud to be part of this effort to help society once
and for all beat the flu.
Courtesy of CDC
2020 Northeast Oregon Health & Wellness Guide
19